RxDoctor Payments Data

Karen Morgenshtern Yacoby, MD

Neurology · Honolulu, HINPI 1497138168

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 69.1% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $4,771, more than ten times the $34 reported in 2020.

$6,683in general payments, 2019–2025

Across 115 payments — averaging $58.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • AbbVie$840
  • AstraZeneca$141
  • Teva Pharmaceuticals USA, Inc.$135
  • Novartis$134
  • Grifols USA, LLC$119
  • plus $694 from 17 others

What the payments were for

  • Consulting fees$91514%
  • Speaking & faculty fees$3,15047%
  • Food & beverage$2,61839%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,683 in reported general payments places this provider in the 70th percentile of 54 neurology providers in Hawaii.

See all neurology providers in Hawaii

Medicare billing

Part B allowed, 2024
$91,031
Medicare patients
80
Services billed
9,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone12$172,214
AubagioTeriflunomide11$98,996
UbrelvyUbrogepant57$88,449
BotoxOnabotulinumtoxina56$72,533
QuliptaAtogepant47$67,171
Nurtec OdtRimegepant Sulfate18$32,326
Ajovy AutoinjectorFremanezumab-Vfrm28$28,452
Emgality SyringeGalcanezumab-Gnlm14$24,381
Aimovig AutoinjectorErenumab-Aooe26$23,672
Memantine Hcl144$5,152
Sumatriptan Succinate45$4,102
Eletriptan HbrEletriptan Hydrobromide13$1,424
RizatriptanRizatriptan Benzoate39$1,397
Naratriptan Hcl31$1,289
Gabapentin34$904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$840$228,153160 claims
PfizerNurtec Odt$4,620$32,32618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 54 neurology providers in Hawaii.

Other neurology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →